“Leveraging deep expertise in advanced synthesis and scalable processing, we can rapidly expand into adjacent natural-product and complex small-molecule families as demand evolves.”
Jørgen Hansen, CSO
Buprenorphine Naloxone Naltrexone
Important molecules for treatment of opioid and alcohol use disorders. We use the power of synthetic biology to produce these important APIs faster and cheaper.
Prostaglandins
.
Powerful lipid-based molecules, used in treatments for reproductive health, glaucoma and cardiovascular treatment. Our microbial production platform enables sustainable, scalable, and cost-effective manufacturing.
Other molecules
.
Our platform enables us to manufacture a broad range of other specialty molecules as APIs or for other high-value applications, supporting both commercial supply and development-stage needs
Integrating Synthetic Biology and Chemistry
Our Hybrid Platform is Solving Industry Challenges
Traditional methods of producing APIs are complex, environmentally challenging and expensive. River Stone Biotech’s manufacturing and process development capabilities couple fermentation with improved chemistry methodology. The combined approach enables flexible intermediates to be taken into more streamlined chemistry conversion processes, driving efficiencies across many criteria. The result is a first-in-kind platform that solves key industry challenges – reducing complexity, waste and cost.
Integrating Synthetic Biology and Chemistry
Our Hybrid Platform is Solving Industry Challenges
Traditional methods of producing APIs are complex, environmentally challenging and expensive. River Stone Biotech’s manufacturing and process development capabilities couple fermentation with improved chemistry methodology. This combination approach enables flexible intermediates to be taken into more streamlined chemistry conversion processes, driving efficiencies across many criteria. The result is a first-in-kind platform that solves key industry challenges – reducing complexity, waste and cost.
“Our result is a first-in-kind platform that solves key industry challenges – reducing complexity, waste and cost.”
Tim Bowser, CTO
Projects and achievements
“Our founding objective was to simplify what was a complex, expensive and environmentally challenging supply chain for specific alkaloid APIs, primarily the APIs used in treatments for opioid use disorder and other substance use disorders – Buprenorphine, Naloxone and Naltrexone”
Projects and achievements
“Our founding objective was to simplify what was a complex, expensive and environmentally challenging supply chain for specific alkaloid APIs, primarily the APIs used in treatments for opioid use disorder and other substance use disorders – Buprenorphine, Naloxone and Naltrexone”
“River Stone Biotech combines synthetic biology using microbes with synthetic chemistry reactions to find new, fast, cost-effective processes and pathways to manufacture active pharmaceutical ingredients such as prostaglandins, buprenorphine, naloxone, naltrexone and other molecules.”
Neil Goldsmith, CBO
RIVER STONE News
Our Hybrid Platform is Solving Industry Challenges
-
Dec. 2025 – New US patent
River Stone Bio has announced the grant of a new patent, Microbial Cell with Improved in vivo Conversion of Thebaine/Oripavine. . Dec. 2025 – New US
-
Nov. 2025 – Production of nororipavine
Yeast based N-demethylation for the production of nororipavine in fed-batch or continuous cultivation . In a groundbreaking paper published in Bioresource
-
Oct. 2025 – Attending CPHI 2025
River Stone will be attending CPHI in Frankfurt next week – october 2025 . RSB is dedicated to providing life changing APIs and formulations via inno
-
Mar. 2025 – Enzyme Discovery and In Vivo Assessment
Plant-Derived UDP-Glycosyltransferases for Glycosylation-Mediated Detoxification of Deoxynivalenol: Enzyme Discovery, Characterization, and In Vivo Resista
-
Jul. 2024 – Glycosylation of aloesone
Enzymatic glycosylation of aloesone performed by plant UDP-dependent glycosyltransferases . In a paper published in Glycobiology, researchers of the Danish
-
Dec. 2023 – Global commercial launch
Advancing to global commercial launch . Cambridge, December 18, 2023 – River Stone Biotech Inc.(RSB), a synthetic biology business centered around a dis
-
Jul. 2022 – Issuance of U.S. Patent
River Stone Biotech Inc. Announces Issuance of U.S. Patent . River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive speci
-
Apr. 2022 – Participation DCAT 2022
River Stone Biotech Inc. participates in DCAT 2022 . River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API
-
Nov. 2021 – $6.8M Series B Financing
River Stone Biotech Inc. Announces $6.8M Series B Financing . Cambridge, Nov. 10, 2021 River Stone Biotech Inc. Announces $6.8M Series B Financing to Adv
-
Dec. 2025 – New US patent
River Stone Bio has announced the grant of a new patent, Microbial Cell with Improved in vivo Conversion of Thebaine/Oripavine. . Dec. 2025 – New US
-
Nov. 2025 – Production of nororipavine
Yeast based N-demethylation for the production of nororipavine in fed-batch or continuous cultivation . In a groundbreaking paper published in Bioresource
-
Oct. 2025 – Attending CPHI 2025
River Stone will be attending CPHI in Frankfurt next week – october 2025 . RSB is dedicated to providing life changing APIs and formulations via inno
-
Mar. 2025 – Enzyme Discovery and In Vivo Assessment
Plant-Derived UDP-Glycosyltransferases for Glycosylation-Mediated Detoxification of Deoxynivalenol: Enzyme Discovery, Characterization, and In Vivo Resista
-
Jul. 2024 – Glycosylation of aloesone
Enzymatic glycosylation of aloesone performed by plant UDP-dependent glycosyltransferases . In a paper published in Glycobiology, researchers of the Danish
-
Dec. 2023 – Global commercial launch
Advancing to global commercial launch . Cambridge, December 18, 2023 – River Stone Biotech Inc.(RSB), a synthetic biology business centered around a dis
-
Jul. 2022 – Issuance of U.S. Patent
River Stone Biotech Inc. Announces Issuance of U.S. Patent . River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive speci
-
Apr. 2022 – Participation DCAT 2022
River Stone Biotech Inc. participates in DCAT 2022 . River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API
-
Nov. 2021 – $6.8M Series B Financing
River Stone Biotech Inc. Announces $6.8M Series B Financing . Cambridge, Nov. 10, 2021 River Stone Biotech Inc. Announces $6.8M Series B Financing to Adv
Get all the news >
Our Hybrid Platform is Solving Industry Challenges
Prostaglandins reactions Opioid reactions Make prostaglandins Make opioids API manufacturer API suppliers Enzymatic conversion Synthetic biology company Synthetic biology APIs Synthesise prostaglandins Synthesise APIs Synthesise opioid Buprenorphine supplier Naloxone supplier Naltrexone supplier Opioid fermentation Prostaglandin fermentation synthesise